# Gyre Therapeutics Inc. (GYRE) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $6.86, market value $727 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Gyre Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 6.1×**. Each dollar of revenue is priced at 6.1×.
- **Price / book: 6.7×**. The shares trade at 6.7× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -2.2%** (5-yr avg -24.4%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -14.0%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: 8.5%**. 8.5% of each dollar of sales reaches the bottom line.
- **Return on equity: 9.3%**. 9.3% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: -19.1%**. Return on all capital, debt included, is -19.1%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -11.8%**. Each dollar of assets produces -11.8% of profit.

## Growth
- **Revenue growth (1 yr): 10.2%** (3-yr 4.5%/yr, 5-yr 41.0%/yr). Revenue grew 10.2% over the last year, against 41.0% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -60.0%** (3-yr -12.6%/yr). Earnings per share fell 60.0%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 2.8×**. It would take 2.8 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 6.28** (quick 6.28). Current assets cover the next year's liabilities 6.28 times.
- **Altman Z-score: 21.03**. A Z-score of 21.03 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Gyre Therapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): -9.5%** (YTD -2.8%, 3-mo 9.1%). The shares are down 9.5% over twelve months including dividends.
- **From 52-week high: -27.2%** (26.1% above the low). Trading 27% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 58**. An RSI of 58 is neutral.
- **Beta (1 yr): 1.28** (volatility 57%). Beta of 1.28 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=GYRE · Page: https://foliofundamentals.com/stocks/gyre

Not investment advice.